Summary of Study ST002153
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001366. The data can be accessed directly via it's Project DOI: 10.21228/M85115 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002153 |
| Study Title | Data from plasma metabolome analysis of APP-KI and Wild type mice treated with B. breve MCC1274 |
| Study Summary | Recently, we showed that administration of B. breve MCC1274 reduced amyloid-beta production, inhibited microglial activation, and suppressed inflammatory responses in the brains of APP knock-in (AppNL-G-F) mice. To elucidate the mechanism of action of this probiotic strain in an Alzheimer's disease-like model, we orally fed 3-month-old mice with B. breve MCC1274 or saline for 4 months and comprehensively investigated metabolites in plasma using CE-FTMS and LC-TOFMS. |
| Institute | Morinaga milk industry CO., LTD. |
| Department | Next generation science institute |
| Laboratory | Frontier research section |
| Last Name | Ohno |
| First Name | Kazuya |
| Address | 1-83 5-Chome Higashihara, Zama-city, Kanagawa-Pref. Japan |
| kazuya-oono443@morinagamilk.co.jp | |
| Phone | 81462523067 |
| Submit Date | 2022-04-18 |
| Analysis Type Detail | LC-MS |
| Release Date | 2022-10-03 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR001366 |
| Project DOI: | doi: 10.21228/M85115 |
| Project Title: | Improvement of cognitive function by B. breve MCC1274 and elucidation of its mechanism of action |
| Project Summary: | Although many studies have suggested that probiotics could modulate various brain functions via the gut-brain axis, little is known about the mechanism underlying this process. We previously reported the beneficial effects of a probiotic strain, Bifidobacterium breve MCC1274, on cognitive function in preclinical and clinical studies. Recently, we showed that administration of this strain reduced amyloid-beta production, inhibited microglial activation, and suppressed inflammatory responses in the brains of APP knock-in (AppNL-G-F) mice. To elucidate the mechanism of action of this probiotic strain in an Alzheimer's disease-like model, we orally fed 3-month-old mice with B. breve MCC1274 or saline for 4 months and comprehensively investigated metabolites in plasma using CE-FTMS and LC-TOFMS. |
| Institute: | Morinaga milk industry CO., LTD. |
| Department: | Next generation science institute |
| Laboratory: | Frontier research section |
| Last Name: | Ohno |
| First Name: | Kazuya |
| Address: | 1-83 5-Chome Higashihara, Zama-city, Kanagawa-Pref. Japan |
| Email: | kazuya-oono443@morinagamilk.co.jp |
| Phone: | 81462523067 |
Subject:
| Subject ID: | SU002239 |
| Subject Type: | Mammal |
| Subject Species: | Mus musculus |
| Taxonomy ID: | 10090 |
| Genotype Strain: | AppNL-G-F or wild type mice |
| Age Or Age Range: | 7 months old |
| Gender: | Male and female |
| Animal Animal Supplier: | RIKEN Center for Brain Science |
| Animal Light Cycle: | 12 hours light and dark cycle |
| Species Group: | Mammals |
Factors:
Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)
| mb_sample_id | local_sample_id | Model | Intervention |
|---|---|---|---|
| SA206357 | AT-1 | Alzheimer’s disease model | B. breve MCC1274 |
| SA206358 | AT-2 | Alzheimer’s disease model | B. breve MCC1274 |
| SA206359 | AT-3 | Alzheimer’s disease model | B. breve MCC1274 |
| SA206360 | AT-4 | Alzheimer’s disease model | B. breve MCC1274 |
| SA206361 | AC-3 | Alzheimer’s disease model | Saline |
| SA206362 | AC-4 | Alzheimer’s disease model | Saline |
| SA206363 | AC-2 | Alzheimer’s disease model | Saline |
| SA206364 | AC-1 | Alzheimer’s disease model | Saline |
| SA206365 | WT-1 | Wild type | B. breve MCC1274 |
| SA206366 | WT-3 | Wild type | B. breve MCC1274 |
| SA206367 | WT-2 | Wild type | B. breve MCC1274 |
| SA206368 | WT-4 | Wild type | B. breve MCC1274 |
| SA206369 | WC-2 | Wild type | Saline |
| SA206370 | WC-3 | Wild type | Saline |
| SA206371 | WC-4 | Wild type | Saline |
| SA206372 | WC-1 | Wild type | Saline |
| Showing results 1 to 16 of 16 |
Collection:
| Collection ID: | CO002232 |
| Collection Summary: | Plasma samples were obtained from AD-like model and wild-type mice orally administered B. breve MCC1274 or saline for 4 months. |
| Sample Type: | Blood (plasma) |
| Storage Conditions: | -80℃ |
Treatment:
| Treatment ID: | TR002251 |
| Treatment Summary: | Three-month-old AppNL-G-F and wild type mice were randomly assigned to a vehicle group and a probiotic group. The vehicle group received saline, and the probiotic group received B. breve MCC1274 (1 × 10＾9 cfu/200 μl saline/mouse) orally 5 times a week for 4 months. |
| Treatment Compound: | Bifidobacterium breve MCC1274 |
| Treatment Route: | oral administration |
| Treatment Dosevolume: | 1 × 10＾9 cfu/200 μl saline |
| Treatment Vehicle: | saline |
Sample Preparation:
| Sampleprep ID: | SP002245 |
| Sampleprep Summary: | For CE-FTMS, 40 µL of plasma was added to 160 µL of methanol containing internal standards at 0°C, 120 µL of Milli-Q water was added and mixed thoroughly, and 240 µL of this mixture was added to a Millipore 5 kDa cutoff filter (ULTRAFREE MC PLHCC, HMT) at 9100 × g for 120 min at 4°C to remove macromolecules. The filtrate was evaporated to dryness under vacuum, dissolved in 40 µL Milli-Q water, and donated to HMT's ω Scan package using capillary electrophoresis Fourier transform mass spectrometry (CE-FTMS).For LC-TOFMS, 80 µL of plasma was added to 240 µL of 1% formic acid/acetonitrile containing internal standards at 0ºC. The mixture was centrifuged at 2,300 x g, 4ºC for 5 min, then centrifuged at 2,300 x g, 4ºC for 5 min, followed by centrifugation of a hybrid SPE phospholipid cartridge (30 mg/mL of hybrid SPE-phospholipid, 30 mg/mL of (SUPELCO) and filtered to remove phospholipids. The filtrate was then evaporated to dryness under nitrogen, dissolved in 80 μL of 50% isopropanol (v/v), and metabolomic analysis was performed using liquid chromatography time-of-flight mass spectrometry (LC-TOFMS). |
Chromatography:
| Chromatography ID: | CH002604 |
| Instrument Name: | Agilent 1260 |
| Column Name: | fused silica capillary (50 μm i.d. × 80 cm total length; Polymicro Technologies, Inc., Phoenix, AZ) |
| Internal Standard: | H3304-1002, Human Metabolome Technologies, Inc. (HMT), Tsuruoka, Yamagata, Japan |
| Solvent A: | commercial electrophoresis buffer (H3301-1001; I3302-1023 for cation; anion analyses, respectively, HMT) |
| Chromatography Type: | Normal phase |
| Chromatography ID: | CH002605 |
| Instrument Name: | Agilent 1200 |
| Column Name: | ODS |
| Internal Standard: | H3304-1002, Human Metabolome Technologies, Inc. (HMT), Tsuruoka, Yamagata, Japan |
| Chromatography Type: | Reversed phase |
Analysis:
| Analysis ID: | AN003526 |
| Analysis Type: | MS |
| Chromatography ID: | CH002604 |
| Num Factors: | 4 |
| Num Metabolites: | 400 |
| Units: | peak area |
| Analysis ID: | AN003527 |
| Analysis Type: | MS |
| Chromatography ID: | CH002605 |
| Num Factors: | 4 |
| Num Metabolites: | 212 |
| Units: | peak area |
